Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585585 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
A Phase 2 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00585585 is a Phase 2 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 1 participants.
The verdict
NCT00585585, a Phase 2 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.
Interventions
- DRUG betahistine dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585585
The ClinicalTrials.gov registry entry for NCT00585585 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which betahistine dihydrochloride is the first listed.
NCT00585585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585585 about?
NCT00585585 is a clinical study titled "Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features". The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporar...
What is the current status of trial NCT00585585?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2007-07. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00585585?
The interventions under investigation include: betahistine dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT00585585?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.